BioForce Nanosciences Reports No Revenue and Increased Losses in Q3 2025

BioForce Nanosciences Holdings, Inc. reported its financial results for the third quarter and the nine months ended September 30, 2025, revealing a continued lack of revenue generation. The company reported no sales for both the three and nine months periods, maintaining a gross profit of $0. Operating expenses for the third quarter totaled $115,915, a slight decrease from $122,024 in the same period last year. For the nine months ended September 30, 2025, total operating expenses increased to $372,153 from $367,277 in the prior year, primarily due to higher general and administrative costs. The net loss for the third quarter was $115,915, compared to a loss of $122,024 in the same quarter of 2024. The nine-month net loss surged to $1,173,346 from $367,277, largely due to an $801,193 loss on liability settlement related to the issuance of shares to cover accrued compensation.

The company's financial position showed significant changes compared to the previous fiscal period. As of September 30, 2025, total assets were reported at $784, a decrease from $862 at the end of 2024. Total liabilities also decreased significantly to $500,722 from $2,302,454, primarily due to a reduction in accrued expenses and liabilities owed to related parties. The accumulated deficit increased to $162,293,512, reflecting ongoing operational losses. The stockholders' deficit improved to $(499,938) from $(2,301,592) at the end of 2024, indicating a reduction in overall financial distress.

Strategically, BioForce has shifted its focus to the nutritional supplement market, particularly through its "BioForce Eclipse" product line. The company aims to enhance brand awareness and drive sales through a dynamic marketing campaign targeting retailers, sporting goods stores, and online platforms. Despite the lack of revenue, management is optimistic about expanding its marketing efforts and establishing vendor relationships to facilitate product distribution. The company has also engaged in related party transactions, including loans from board members to support operations, which underscores the ongoing need for capital to sustain business activities.

Operationally, BioForce has not reported any customer counts or product adoption rates, as it has not generated sales during the reporting periods. The company continues to explore avenues for geographic expansion and product distribution, with plans to market its products through various retail channels across the United States. The employee headcount remains unspecified, but the company is actively seeking to implement its business plan to generate revenue and improve its financial standing.

Looking ahead, BioForce Nanosciences Holdings, Inc. acknowledges the challenges it faces in achieving profitability and sustaining operations without additional financing. The management has expressed a commitment to executing its business strategy and expanding its market presence, although there are no guarantees of success. The company’s ability to continue as a going concern is contingent upon its capacity to raise funds and generate revenue, as indicated in its financial statements.